Klotho Neurosciences, Inc. (KLTO) - Total Liabilities
Based on the latest financial reports, Klotho Neurosciences, Inc. (KLTO) has total liabilities worth $145.89K USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Klotho Neurosciences, Inc. - Total Liabilities Trend (2021–2024)
This chart illustrates how Klotho Neurosciences, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See working capital position of Klotho Neurosciences, Inc. to evaluate short-term liquidity relative to the company's equity base.
Klotho Neurosciences, Inc. Competitors by Total Liabilities
The table below lists competitors of Klotho Neurosciences, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Logan Ridge Finance Corp
NASDAQ:LRFC
|
USA | $101.89 Million |
|
SRM Entertainment, Inc. Common Stock
NASDAQ:SRM
|
USA | $751.58K |
|
SuperCom Ltd
F:50S
|
Germany | €28.23 Million |
|
Pacific Pipe Public Company Limited
BK:PAP
|
Thailand | ฿1.99 Billion |
|
The LEADCORP Inc
KQ:012700
|
Korea | ₩595.00 Billion |
|
Latitude Tree Holdings Bhd
KLSE:7006
|
Malaysia | RM140.25 Million |
|
Sea & Land Integrated Co
TWO:5603
|
Taiwan | NT$714.96 Million |
|
INLIF LIMITED Ordinary Shares
NASDAQ:INLF
|
USA | $8.64 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Klotho Neurosciences, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Klotho Neurosciences, Inc..
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 83.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.01 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Klotho Neurosciences, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Klotho Neurosciences, Inc. (2021–2024)
The table below shows the annual total liabilities of Klotho Neurosciences, Inc. from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.27 Million | -21.53% |
| 2023-12-31 | $1.62 Million | +19.17% |
| 2022-12-31 | $1.36 Million | +8887.60% |
| 2021-12-31 | $15.13K | -- |
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed it… Read more